

S5 Table. Comparison of baseline characteristics from included and targeted studies

| Characteristic | Included studies (n=42) | Targeted studies* (n=25) |
|---------------------------|----------------------------|-----------------------------|
| Region | | |
| Asia-Pacific, studies (%) | 39 (92.9) | 18 (72.0) |
| Africa, studies (%) | 1 (2.4) | 6 (24.0) |
| The Americas, studies (%) | 2 (4.8) | 1 (4.0) |
| Year of enrolment†‡ | | |
| Pre-2009, studies (%) | 31 (75.6) | 15 (60.0) |
| 2009-2017, studies (%) | 10 (24.4) | 10 (40.0) |
| Age (years), median (IQR) | 17.0 (9.0, 29.0) | 23.4 (17.1, 24.7)§ |
| Male, % of patients | 63.3 | 68.0¶ |

*Age and male percentage of targeted studies frequency weighted according to number of patients treated with artemisinin-based combination therapy; † Year of enrolment defined as the year study enrolment completed; ‡ Year of enrolment not available from one included study; § Mean age not available from nine studies; ¶ Percentage based on frequency weighted median, percentage not available from five studies